1 July 2020 in Journal of Biological Chemistry
Emergence of resistance to available anti-leishmanial drugs advocates identification of new drug targets and their inhibitors for visceral leishmaniasis. Here, we identified heat shock protein 78 in Leishmania donovani (LdHSP78), a putative ClpB protease, as important for parasite infection of host macrophages and a potential therapeutic target. Enrichment of LdHSP78 in infected humans, hamsters and parasite amastigotes suggested its importance for disease persistence. Heterozygous knockouts of L. donovani (LdHSP78+/-) and L. mexicana (LmxHSP78+/-) were generated using flanking untranslated region (UTR) based multi-fragment ligation strategy and CRISPR-Cas9 technique, respectively to investigate the significance of HSP78 for disease manifestation. LdHSP78+/- parasite burden was dramatically reduced in both murine bone marrow–derived macrophages and hamsters, associated with enrichment of pro-inflammatory cytokines and nitric oxide (NO). This finding implies that LdHSP78+/- parasites cannot suppress immune activation and escape NO-mediated toxicity in macrophages. Further, phosphorylation of the mitogen-activated protein kinase (MAPK) p38 was enhanced, and phosphorylation of extracellular signal–regulated kinase 1/2 (ERK1/2) was decreased in cells infected with LdHSP78+/- compared to wildtype (WT) infection. Virulence of the LdHSP78+/- strain was restored by episomal addition of LdHSP78 gene. Finally, using high-throughput virtual screening, we identified P1,P5-di(adenosine-5’)-penta-phosphate ammonium salt (Ap5A) as an LdHSP78 inhibitor. It selectively induced amastigote death at doses similar to amphotericin B (AmB) dosing, while exhibiting much less cytotoxicity toward healthy macrophages than AmB. In summary, using both a genetic knockout approach and pharmacological inhibition, we establish LdHSP78 as a drug target and Ap5A as a potential lead for improved anti-leishmanial agents.
12 August 2021 in The FASEB Journal
26 December 2021 in Allergy
3 November 2021 in Current Opinion in Allergy and Clinical Immunology
Purpose of review: The purpose of this review is to provide a comprehensive summary of the current understanding of the pathogenesis of aspirin-exacerbated respiratory disease (AERD), and an update on its management. Recent findings: Elevated levels of 15-oxo-eicosatetraenoic acid (15-Oxo-ETE), a newly described metabolite of arachidonic acid, have been identified in nasal polyps of AERD patients. In nasal polyps, activated basophils, and interleukin-5 -receptor-α-positive IL-5Rα+ plasma cells are associated with more severe nasal polyposis in AERD. Alveolar monocyte-derived macrophages and their persistent proinflammatory activation were suggested as putative factors contributing to AERD. Although not AERD-specific, three biological agents are now available for the management of both nasal polyposis and asthma. Summary: A newly downstream product of 15-lipoxygenase, 15-Oxo-ETE, was recently found to be significantly elevated in nasal polyps from AERD patients. This eicosanoid metabolite likely originates from an interplay between epithelial cells and mast cells. Nasal polyp basophils, IL-5Rα+ plasma cells, and alveolar macrophages were identified as important contributors to inflammation in AERD. Besides traditional aspirin desensitization and treatment for AERD management, several biologics for treatment of asthma are available, including three that have been approved for nasal polyposis. These biologic agents show variable rates of success in controlling AERD symptoms.
25 February 2026 in Neuro-Oncology
Background: Immunotherapy has yet to make significant gains in glioblastoma (GBM) treatment, due in part to GBM-mediated immune suppression. Increasing evidence points to critical roles for tumor-derived extracellular vesicles (EVs) and immunosuppressive myeloid cells as key factors in this process. Methods: Immunophenotyping of the tumor-immune microenvironment was performed using ultrasonic aspirate collected during GBM resection by high-dimensional flow cytometry. EVs collected from patient-derived GBM cell lines were used to condition myeloid cells collected from healthy donors to generate immunosuppressive myeloid cells. siRNA was used to knockdown TIGIT and/or NLRP3 expression prior to EV conditioning. T cell co-culture studies were performed with donor-matched T cells. Results: Immune phenotyping of the tumor microenvironment and EV-conditioned myeloid cells revealed similar immunomodulatory protein expression across myeloid cell populations, with particularly elevated TIGIT expression. Knockdown of TIGIT reduced the immunosuppressive polarization of myeloid cells, resulting in improved T cell function. This finding proceeded in an NLRP3-dependent manner, with substantial co-expression of TIGIT and NLRP3 expression prior to knockdown, and concomitant knockdown of NLRP3 abrogating the effect of TIGIT knockdown. TIGIT expression correlated with increased IL-13 expression, and IL-13 blockade unmasked a pro-inflammatory myeloid cell phenotype. Conclusion: TIGIT expression in myeloid cells in the GBM microenvironment is a functional marker of immunosuppressive activity, with TIGIT knockdown reducing IL-13 expression and unmasking the pro-inflammatory activity of NLRP3. This study bolsters our understanding of the immunosuppressive complexities of the GBM microenvironment and supports attenuation of immunosuppressive myeloid cell activity as a strategy to restore immune function in GBM.